Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
COMPASS Pathways plc is a clinical-stage biopharmaceutical company focused on developing psychedelic-inspired therapies for serious mental health conditions. The company operates within the biopharmaceutical and mental health therapeutics industries, with a primary focus on treatment-resistant depression (TRD). Its core product candidate, COMP360 psilocybin therapy, combines a proprietary, synthesized formulation of psilocybin with psychological support and is designed to be administered in controlled clinical settings.
Founded in 2016, COMPASS Pathways was established to address significant unmet needs in mental health care using evidence-based psychedelic science. The company has positioned itself as a leader in the regulated development of psilocybin therapies by emphasizing pharmaceutical-grade manufacturing, standardized therapeutic protocols, and large-scale randomized clinical trials. It became a publicly traded company in 2020 following its initial public offering on Nasdaq, marking a significant milestone in the commercialization of psychedelic-based medicine.
Business Operations
COMPASS Pathways operates primarily as a research and development organization with a single reportable operating segment focused on the development of COMP360 psilocybin therapy. Revenue generation to date has been limited and consists primarily of collaboration and grant-related income, as the company does not yet have approved commercial products. Its core activities include clinical trial execution, drug manufacturing, regulatory engagement, and intellectual property development.
The company conducts multi-site clinical trials across North America and Europe and controls key assets including its proprietary COMP360 formulation, therapy manuals, digital training platforms for therapists, and a portfolio of patents covering synthesis, formulation, and therapeutic use. COMPASS Pathways maintains relationships with academic institutions, clinical research organizations, and healthcare providers but does not currently report material joint ventures or revenue-generating subsidiaries. Available public disclosures indicate no conflicting information regarding its operating structure.
Strategic Position & Investments
Strategically, COMPASS Pathways is focused on advancing COMP360 psilocybin therapy through late-stage clinical development for TRD, with additional exploratory studies in other difficult-to-treat mental health conditions. Its growth strategy centers on achieving regulatory approval in major markets, establishing scalable therapist training infrastructure, and building payer and healthcare system engagement ahead of potential commercialization.
The company has invested heavily in clinical trials, intellectual property protection, and manufacturing capabilities to support potential global deployment. COMPASS Pathways does not report ownership of a diversified portfolio of operating subsidiaries or unrelated investments; rather, it maintains a concentrated strategy around its lead program. Emerging areas of involvement include digital tools to support therapy delivery and long-term outcome tracking. No material acquisitions have been conclusively disclosed beyond routine asset and IP transactions, and available public sources do not indicate conflicting data.
Geographic Footprint
COMPASS Pathways is headquartered in London, United Kingdom, with a significant operational presence in the United States, including executive leadership and clinical operations. The company’s clinical trials and research activities span Europe and North America, reflecting its focus on regulatory pathways in both regions.
Its international footprint is primarily research- and trial-based rather than commercial, as no products have yet been approved for sale. The company’s global influence is driven through multinational clinical studies, engagement with regulatory authorities such as the U.S. FDA and European regulators, and collaborations with research institutions across multiple countries. Data regarding operations outside these regions is limited, and no verified evidence suggests material operations in other continents.
Leadership & Governance
COMPASS Pathways was co-founded by George Goldsmith, who has played a central role in shaping the company’s mission to develop regulated psychedelic therapies grounded in clinical evidence. The leadership team emphasizes a strategy focused on scientific rigor, patient safety, and regulatory compliance as foundational principles for long-term value creation.
Key executives and board-linked leadership include:
- Kabir Nath – Chief Executive Officer
- George Goldsmith – Co-Founder and Executive Chairman
- Lori Englebert – Chief Financial Officer
- Holly Fernandez Lynch – Chief Bioethics Officer
- Guy Goodwin – Chief Medical Officer
The governance structure reflects a blend of pharmaceutical, regulatory, financial, and academic expertise. Public disclosures across filings and investor communications are generally consistent regarding leadership roles; no material discrepancies were identified in available public sources.